financetom
Business
financetom
/
Business
/
WW Grainger cuts 2024 sales forecast on slow demand
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
WW Grainger cuts 2024 sales forecast on slow demand
Aug 1, 2024 6:37 AM

Aug 1 (Reuters) - Industrial maintenance and safety

products supplier WW Grainger Inc ( GWW ) on Thursday lowered

its annual sales forecast due to slower-than-expected demand,

sending its shares down 4% in premarket trading.

The Lake Forest, Illinois-based company now expects 2024

sales to be between $17 billion and $17.3 billion, down from its

previous forecast of $17.2 billion to $17.7 billion, issued in

April.

The company provides hand tools, power tools and industrial

products to home improvement retailers, construction businesses

and aerospace manufacturers.

Second-quarter sales for the company, which competes with

Fastenal ( FAST ) and WESCO, rose 3.1% to $4.31 billion.

Adjusted per-share earnings for the quarter ended June 30

was $9.76, up from $9.28 a year earlier.

The stock until the last close had gained 18% so far this

year.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
MoonLake Says Lead Drug Shows Durable Response, Eyes FDA Filing
Mar 30, 2026
MoonLake Immunotherapeutics ( MLTX ) shares are volatile on Monday as the company is reporting long-term results from its VELA-1 and VELA-2 Phase 3 clinical trials of sonelokimab in patients with hidradenitis suppurativa (HS). HS is a chronic, non-contagious inflammatory skin condition, often called acne inversa, that causes painful, recurring lumps or abscesses, primarily in sweat gland areas like the...
Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says
Alumis' Drug 'Very Positive' for Treatment of Psoriasis, Systemic Lupus Erythematosus, Oppenheimer Says
Mar 30, 2026
11:25 AM EDT, 03/30/2026 (MT Newswires) -- Alumis' ( ALMS ) recent phase 3 results for its psoriasis treatment envudeucitinib is very positive for the company, Oppenheimer said in a note emailed Monday. Envudeucitinib had similar efficacy as Johnson & Johnson's ( JNJ ) icotrokinra and Takeda Pharmaceutical's ( TAK ) zasocitinib, while the Alumis ( ALMS ) drug had...
Verisk Analytics Q1 Results Seen Inline, Fiscal 2026 Guidance Reiteration Likely, RBC Says
Verisk Analytics Q1 Results Seen Inline, Fiscal 2026 Guidance Reiteration Likely, RBC Says
Mar 30, 2026
10:56 AM EDT, 03/30/2026 (MT Newswires) -- Verisk Analytics' ( VRSK ) Q1 results are expected to be inline and the company will likely reiterate its fiscal 2026 guidance, RBC Capital Markets said. The brokerage said in a Friday note that Verisk's defensive business remains well-positioned amid macroeconomic uncertainty, while its $1.5 billion accelerated share repurchase agreement should provide downside...
Insmed Sees Rising Physician Adoption of Brinsupri, Morgan Stanley Says
Insmed Sees Rising Physician Adoption of Brinsupri, Morgan Stanley Says
Mar 30, 2026
11:24 AM EDT, 03/30/2026 (MT Newswires) -- Insmed ( INSM ) is seeing growing physician adoption of its Brinsupri therapy, with new survey data indicating expanding use and rising confidence in the drug's long-term potential, Morgan Stanley said in a report Monday. Brinsupri is a prescription drug developed by Insmed ( INSM ) to treat non-cystic fibrosis bronchiectasis. A survey...
Copyright 2023-2026 - www.financetom.com All Rights Reserved